<DOC>
	<DOCNO>NCT00767819</DOCNO>
	<brief_summary>The purpose multicenter , two-arm , exact binomial single-stage , phase II trial determine preliminary efficacy safety RAD001 patient histological evidence progressive metastatic bone soft tissue sarcoma .</brief_summary>
	<brief_title>Treatment Patients With RAD001 Who Have Progressive Sarcoma</brief_title>
	<detailed_description />
	<mesh_term>Sarcoma</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<criteria>Histological evidence progressive metastatic bone soft tissue sarcoma . The following tumor type include : malignant fibrous histiocytoma liposarcoma synovial sarcoma malignant paraganglioma fibrosarcoma leiomyosarcoma angiosarcoma include haemangiopericytoma malignant peripheral nerve sheath tumor STS , otherwise specify miscellaneous sarcoma include mixed mesodermal tumor uterus osteosarcoma Ewing 's sarcoma rhabdomyosarcoma gastrointestinal stromal tumor ( failure intolerance imatinib sunitinib 1st 2nd line ) alveolar soft part sarcoma ( ASPS ) Objective progression disease may document RECIST criterion . Any follow would sufficient accord RECIST : 20 % increase sum unidimensionally measure target lesion new lesion unequivocal increase nonmeasurable disease . Patients must disease amenable surgery , radiation , combine modality therapy curative intent . ECOG performance status 0 2 . Anticancer therapy within 3 week enrollment include chemotherapy , hormonal therapy , immunotherapy , radiotherapy . The following tumor type include : gastrointestinal stromal tumor ( except patient treatment imatinib sunitinib 1st 2nd line ) chondrosarcoma malignant mesothelioma neuroblastoma . Prior therapy RAD001 ( everolimus ) rapamycins ( sirolimus , temsirolimus ) . Neurotoxicity &gt; grade 2 CTC . Radiation lung . Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>progressive GIST</keyword>
	<keyword>progressive sarcoma</keyword>
</DOC>